Intravenous ivabradine versus placebo in patients with low cardiac output syndrome treated by dobutamine after elective coronary artery bypass surgery: a phase 2 exploratory randomized controlled trial

Nguyen, Lee S.; Squara, Pierre; Amour, Julien; Carbognani, Daniel; Bouabdallah, Kamel; Thierry, Stéphane; Apert-Verneuil, Caroline; Moyne, Aurélie; Cholley, Bernard

doi:10.1186/s13054-018-2124-8

Critical Care

Table 2 Hemodynamic variations between treatment initiation and cessation

From: Intravenous ivabradine versus placebo in patients with low cardiac output syndrome treated by dobutamine after elective coronary artery bypass surgery: a phase 2 exploratory randomized controlled trial

		Ivabradine group (n = 14)			Placebo group (n = 5)
		Median	[Q1–Q3]	P value^†	Median	[Q1–Q3]	P value^†
SBP, mm Hg	H0	110	[93–118]	<0.05	111	[92–128]	ns
SBP, mm Hg	Last value	125	[114–139]	<0.05	111	[90–121]	ns
DBP, mm Hg	H0	62	[55–71]	ns	51	[50–61]	ns
DBP, mm Hg	Last value	59	[48–62]	ns	55	[48–67]	ns
MBP, mm Hg	H0	78	[66–83]	ns	72	[68–84]	ns
MBP, mm Hg	Last value	80	[75–82]	ns	74	[60–83]	ns
SV, mL	H0	37	[32–55]	<0.001	55	[40–58]	ns
SV, mL	Last value	60	[49–79]	<0.001	62	[40–73]	ns
CO, L.min⁻¹	H0	4.7	[3.6–5.4]	<0.05	5.4	[3.3–6.2]	ns
CO, L.min⁻¹	Last value	5.3	[4.5–6.5]	<0.05	5.9	[3.9–7.2]	ns
CI, L.min^− 1.m⁻²	H0	2.5	[2.0–2.8]	<0.05	2.6	[1.7–3.1]	ns
CI, L.min^− 1.m⁻²	Last value	2.9	[2.4–3.4]	<0.05	3.2	[2.4–3.4]	ns
LVSWI, g.m.m^− 2	H0	20.0	[13.7–21.7]	<0.05	18.8	[13.9–31.9]	ns
LVSWI, g.m.m^− 2	Last value	27.7	[18.5–32.4]	<0.05	20.5	[17.4–34.7]	ns
SvO₂ (%)	H0	71	[65–79]	ns	76	[75–85]	ns
SvO₂ (%)	Last value	72	[57–79]	ns	81	[76–84]	ns
PCWP, mm Hg	H0	18	[15–21]	ns	17	[16–17]	ns
PCWP, mm Hg	Last value	14	[12–18]	ns	13	[11–18]	ns
RAP, mm Hg	H0	15	[10–17]	ns	14	[10–14]	ns
RAP, mm Hg	Last value	11	[11–15]	ns	14	[12–18]	ns
Diuresis, mL.kg⁻¹.h⁻¹	H0	1.20	[0.76–3.00]	ns	2.50	[1.42–2.69]	ns
Diuresis, mL.kg⁻¹.h⁻¹	Last value	0.80	[0.39–1.08]	ns	0.60	[0.29–0.82]	ns
eGFR, mL.min⁻¹	H0	82	[67–110]	na	82	[76–119]	na
eGFR, mL.min⁻¹	Last value	76	[62–100]	na	62	[60–67]	na
Lactate, mmol/L	H0	1.9	[1.3–2.8]	ns	2.1	[1.4–2.9]	ns
Lactate, mmol/L	Last value	1.7	[1.2–2.5]	ns	1.2	[1.1–1.7]	ns
Troponin Ic, μg/L	H0	0.90	[0.36–3.00]	ns	2.00	[1.20–5.20]	ns
Troponin Ic, μg/L	Last value	2.70	[0.86–4.33]	ns	1.00	[0.89–4.20]	ns

^†Intragroup comparison between H0 and last value under treatment. Abbreviations: CI cardiac index, CO cardiac output, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate (calculated with Cockcroft-Gault formula), H0 before study treatment initiation, Last value last value under treatment, LVSWI left ventricular stroke work index, MBP mean blood pressure, na not appropriate due to the small sample size (seven patients in the ivabradine group and two patients in the placebo group), ns not significant, PCWP pulmonary capillary wedged pressure, RAP right atrial pressure, SBP systolic blood pressure, SV stroke volume, SvO₂ venous blood oxygen saturation

Back to article page

ISSN: 1364-8535

Contact us

Submission enquiries: journalsubmissions@springernature.com